Abbott Hepatitis C Combo Impressive in Small Study
April 6, 2012
A combination of oral hepatitis C drugs being developed by Abbott Laboratories realized cure rates exceeding 90 percent in treatment-naïve patients, according to a small, mid-stage study. The results, released Wednesday, will be presented later this month in Barcelona at a meeting of the European Association for the Study of the Liver.
For 12 weeks, patients in the Phase II trial, known as "Co-Pilot," received Abbott's protease inhibitor ABT-450, boosted by the antiviral drug ritonavir with its polymerase inhibitor ABT-333, and ribavirin, which is used in all current hepatitis C regimens. Patients' blood virus levels were checked 24 weeks later for a sustained virologic response. Those achieving SVR were considered cured.View Full Article
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)